Seven non-differentially expressed 'dark biomarkers' show transcriptional dysregulation in chronic lymphocytic leukemia.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2023-03-01 DOI:10.2217/pme-2022-0123

Ruihao Xin, Xin Feng, Hang Zhang, Yueying Wang, Meiyu Duan, Tunyang Xie, Lin Dong, Qiong Yu, Lan Huang, Fengfeng Zhou

{"title":"Seven non-differentially expressed 'dark biomarkers' show transcriptional dysregulation in chronic lymphocytic leukemia.","authors":"Ruihao Xin, Xin Feng, Hang Zhang, Yueying Wang, Meiyu Duan, Tunyang Xie, Lin Dong, Qiong Yu, Lan Huang, Fengfeng Zhou","doi":"10.2217/pme-2022-0123","DOIUrl":null,"url":null,"abstract":"Aim: Transcriptional regulation is actively involved in the onset and progression of various diseases. This study used the feature-engineering approach model-based quantitative transcription regulation to quantitatively measure the correlation between mRNA and transcription factors in a reference dataset of chronic lymphocytic leukemia (CLL) transcriptomes. Methods: A comprehensive investigation of transcriptional regulation changes in CLL was conducted using 973 samples in six independent datasets. Results & conclusion: Seven mRNAs were detected to have significantly differential model-based quantitative transcription regulation values but no differential expression between CLL patients and controls. We called these genes 'dark biomarkers' because their original expression levels did not show differential changes in the CLL patients. The overlapping lncRNAs might have contributed their transcripts to the expression miscalculations of these dark biomarkers.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"143-155"},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0123","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: Transcriptional regulation is actively involved in the onset and progression of various diseases. This study used the feature-engineering approach model-based quantitative transcription regulation to quantitatively measure the correlation between mRNA and transcription factors in a reference dataset of chronic lymphocytic leukemia (CLL) transcriptomes. Methods: A comprehensive investigation of transcriptional regulation changes in CLL was conducted using 973 samples in six independent datasets. Results & conclusion: Seven mRNAs were detected to have significantly differential model-based quantitative transcription regulation values but no differential expression between CLL patients and controls. We called these genes 'dark biomarkers' because their original expression levels did not show differential changes in the CLL patients. The overlapping lncRNAs might have contributed their transcripts to the expression miscalculations of these dark biomarkers.

查看原文本刊更多论文

7个非差异表达的“暗生物标志物”显示慢性淋巴细胞白血病的转录失调。

目的:转录调控积极参与多种疾病的发生和发展。本研究采用基于特征工程方法模型的定量转录调控，定量测量了慢性淋巴细胞白血病(CLL)转录组参考数据集中mRNA与转录因子之间的相关性。方法:利用6个独立数据集的973个样本，对CLL的转录调控变化进行全面研究。结果与结论:检测到7种mrna在CLL患者和对照组之间具有显著差异的基于模型的定量转录调控值，但无差异表达。我们称这些基因为“暗生物标志物”，因为它们的原始表达水平在CLL患者中没有表现出差异变化。重叠的lncrna可能导致了这些黑暗生物标志物的表达错误。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.